Patents by Inventor Özlem Türeci

Özlem Türeci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapy involving antibodies against Claudin 18.2 for treatment of cancer
    Patent number: 11395852
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: July 26, 2022
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Özlem Türeci
  • THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20220184209
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Inventors: Ugur Sahin, Özlem Türeci
  • Claudin-6-specific immunoreceptors and t cell epitopes
    Patent number: 11345731
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: May 31, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, TRON-Translationale Onkologie An Der Universitatsmedzin Der Johannes Gutenberg-Universitat Mainz, Ganymed Pharmaceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • ANTIBODIES USEFUL IN CANCER DIAGNOSIS
    Publication number: 20220162302
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 26, 2022
    Inventors: Rita MITNACHT-KRAUS, Stefan WÖLL, Korden WALTER, Özlem TÜRECI, Ugur SAHIN
  • Antibodies useful in cancer diagnosis
    Patent number: 11279757
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: March 22, 2022
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh
    Inventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
  • MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER
    Publication number: 20200385448
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 10, 2020
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
    Publication number: 20200339677
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 29, 2020
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
  • Antibodies specific for claudin 6 (CLDN6)
    Patent number: 10745477
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: August 18, 2020
    Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
  • Monoclonal antibodies against claudin-18 for treatment of cancer
    Patent number: 10738108
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 11, 2020
    Assignees: Astellas Pharma Inc., TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • ANTIBODIES USEFUL IN CANCER DIAGNOSIS
    Publication number: 20200199221
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Application
    Filed: September 5, 2018
    Publication date: June 25, 2020
    Inventors: Rita MITNACHT-KRAUS, Stefan WÖLL, Korden WALTER, Özlem TÜRECI, Ugur SAHIN
  • CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20190389920
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 26, 2019
    Inventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina Anna MROZ
  • BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES
    Publication number: 20190309067
    Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: September 20, 2017
    Publication date: October 10, 2019
    Inventors: Ugur Sahin, Christiane Stadler, Leyla Fischer, Arne Jendretzki, Özlem Türeci, Fabrice Le Gall, Maria Kreuzberg
  • Genetic products differentially expressed in tumors and the use thereof
    Patent number: 10414824
    Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: September 17, 2019
    Assignee: GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Claudin-6-specific immunoreceptors and T cell epitopes
    Patent number: 10370423
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: August 6, 2019
    Assignees: Biotech Cell & Gene thrapies GMBH, Tron—Translationale Onkologie Ander Universitata tsmedizin Der Johannes Gutenberg-Universitat Main, Ganymed Pharmceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • Identification of tumor-associated markers for diagnosis and therapy
    Patent number: 10253373
    Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 9, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
    Publication number: 20190076525
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Application
    Filed: October 11, 2018
    Publication date: March 14, 2019
    Inventors: Ugur Sahin, Özlem Türeci
  • Monoclonal antibodies against claudin-18 for treatment of cancer
    Patent number: 10174104
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: January 8, 2019
    Assignee: GANYMED PHARMACEUTICALS GMBH
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • Therapy involving antibodies against Claudin 18.2 for treatment of cancer
    Patent number: 10137195
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 27, 2018
    Assignees: Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
    Inventors: Ugur Sahin, Özlem Türeci
  • Monoclonal antibodies for treatment of cancer
    Patent number: 10125196
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: November 13, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
    Inventors: Ugur Sahin, Michael Koslowski, Özlem Türeci
  • Identification of surface-associated antigens for tumor diagnosis and therapy
    Patent number: 10036753
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: July 31, 2018
    Assignee: GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schlüter